Korean J Geriatr Gerontol.  2016 Dec;17(2):74-78. 10.15656/kjcg.2016.17.2.74.

Prognostic Evaluation through Cardiac ¹²³I-Metaiodobenzylguanidine Image in Parkinson’s Disease (Pilot Study)

• Ho SH
• Song IU
• Chung YA

• KMID: 2566502
• DOI: http://doi.org/10.15656/kjcg.2016.17.2.74

Abstract

Background
¹²³I-metaiodobenzylguanidine (MIBG) image is a well-known tool to evaluate cardiac sympathetic denervation in the idiopathic Parkinson’s disease (PD). Therefore, MIBG images have been reported as a useful tool for diagnosing PD and differentiating PD from other diseases with parkinsonian clinical features. However, relationship between MIBG images and prognosis in PD are unclear. Therefore, we investigated via this study whether MIBG image have a role as predictor of the progression of symptoms in PD or not.
Methods
We prospectively enrolled 20 patients with PD who also had decreased striatal uptake on FP-CIT PET/CT. All subjects underwent cardiac ¹²³I-MIBG planar scintigraphy and SPECT separately. Myocardial ¹²³I-MIBG uptake was interpreted on planar and SPECT/CT images separately by visual and quantitative analysis. The clinical evaluations were assessed according to the Hoehn and Yahr (HY) stage, the Unified PD Rating Scale (UPDRS) and general neuropsychological tests on 1 year after first diagnosis.
Results
All PD patients showed more severe HY stage and UPDRS motor part on 1-year follow-up than first visit (baseline). However, there was no difference of HY stage, UPDRS motor and neuropsychological tests between PD-Def and PD-NL on 1-year follow-up.
Conclusion
We cannot find a role of ¹²³I-MIBG as predictor of disease progression in PD in this study. In addition, we suggest that further researches with larger study populations need to be done to clarify the role of ¹²³I-MIBG image as biomarker of disease progression in PD.

Keyword

Parkinson’s disease; ¹²³I-metaiodobenzylguanidine; Predictor; Biomarker